Patent · US Active

Cyclic monomer and dimer peptides having integrin antagonist activity

US10301371B2 · kind B2 · utility

16Cited by

25References

14Claims

0Family size

Assignee

Protagonist Therapeutics, Inc. · US

Inventors

Ashok Bhandari · Pleasanton, US
Dinesh V. Patel · Fremont, US
Genet Zemede · San Jose, US

Key dates

Filing date	Oct 1, 2015
Grant date	May 28, 2019
Priority date	—
Expiry date	Oct 1, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to C to N cyclized (C-N cyclic) monomer and dimer peptide molecules, as well as peptide dimers which are connected by linker moieties at the N terminus and the C terminus of each peptide subunit, which inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against α4β1 binding.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.